Breast Cancer Cases Will Hit 3.5 Million Annually by 2050, Driven by a Crisis in Low-Income Countries

Breast cancer killed an estimated 764,000 women in 2023. By 2050, if current trajectories hold, that annual toll will reach nearly 1.4 million - a 44% increase driven not by failures in wealthy countries, where survival has improved substantially, but by an accelerating burden in low- and middle-income countries that lack the diagnostic infrastructure and treatment access to keep pace.

That is the central finding of a major analysis published in The Lancet Oncology, produced by the Global Burden of Disease Study Breast Cancer Collaborators using data from population-based cancer registries, vital registration systems, and caregiver interviews across 204 countries and territories. The study covers 1990 to 2023 and projects forward to 2050.

Two Very Different Trajectories

The divergence between high-income and low-income countries is the defining feature of the data. In 2023, high-income countries recorded the highest age-standardized incidence rates - Monaco, Andorra, France, Germany, and Ireland all exceeded 100 new cases per 100,000 women. But while rates in these countries have remained broadly stable or declined, age-standardized incidence rates in low-income countries rose 147% on average between 1990 and 2023.

The mortality picture is even more striking. Between 1990 and 2023, age-standardized death rates in high-income countries fell 30% - a consequence of better screening, earlier diagnosis, and more effective treatment. In low-income countries over the same period, mortality rates nearly doubled to 24 deaths per 100,000 women, exceeding the 16 per 100,000 rate now seen in high-income countries.

This reversal reflects a profound healthcare inequality. Women in low-income countries who develop breast cancer are more likely to be diagnosed at a later stage, when treatment is harder and survival less likely. They face shortages of radiotherapy machines, limited access to chemotherapy, inadequate pathology services, and costs for standard treatments that are catastrophic relative to household incomes.

"LMICs are hit hardest by escalating breast cancer burden as many of these nations grapple with lifestyle and demographic changes alongside health systems that are less equipped than ideal to respond," said co-author Dr. Olayinka Ilesanmi, a physician and epidemiologist from Nigeria working for the Africa CDC.

Modifiable Risk Factors: Where Prevention Is Possible

The analysis identifies six modifiable risk factors collectively linked to 28% of the global breast cancer burden - approximately 6.8 million years of healthy life lost in 2023 alone. High red meat consumption had the largest individual contribution, accounting for nearly 11% of all healthy life lost to breast cancer globally. Tobacco use, including secondhand smoke, contributed 8%; high blood sugar contributed 6%; high body mass index contributed 4%; and high alcohol consumption and low physical activity each contributed approximately 2%.

Progress on some of these fronts is visible. The breast cancer burden attributable to high alcohol use declined 47% between 1990 and 2023; the burden from tobacco declined 28%. For other risk factors, however - particularly high BMI and high blood sugar - the trends are moving in the wrong direction.

The analysis also surfaces a concerning pattern in younger women. While breast cancer remains far more common in women over 55, incidence rates in women aged 20 to 54 rose 29% between 1990 and 2023. The underlying drivers of this rise - changing hormonal exposures, dietary patterns, physical activity levels - require more granular research to fully understand.

The Scale of What Is Lost

The study measures burden not only in cases and deaths but in disability-adjusted life years - years of healthy life lost to illness, disability, and premature death. By that metric, the global breast cancer burden more than doubled between 1990 and 2023, from 11.7 million to 24 million years lost. Women in low- and lower-middle-income countries, who account for 27% of global cases, contribute more than 45% of all disability-adjusted life years lost - a ratio that reflects both later-stage diagnosis and the absence of effective treatment.

Several important limitations apply. The study relies on the quality of cancer registry data, which varies enormously between countries and is particularly limited in low-income settings. Cancer stage at diagnosis and molecular subtype are not captured, despite their strong influence on survival. The analysis does not account for the disruptions caused by COVID-19 or recent conflicts on cancer surveillance or treatment delivery.

An independent commentator noted that without ethnic or genetic ancestry data, the study cannot separate genetic predisposition from environmental exposures or healthcare disparities as drivers of regional differences. These refinements will be necessary for the study's findings to translate into targeted cancer control strategies at the national level.